Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2.
Journal: Science advances
Published: November 12, 2025
Long-Term Correction of Murine Glycogen Storage Disease Type III by AAV-Mediated Gene Therapy Using an Immunotolerizing Dual Promoter to Express Bacterial Pullulanase.
Journal: Advances in cell and gene therapy
Published: October 08, 2025
Systemic Disease Progression and Neurodegeneration in the Gbe1ys/ys Mouse Model of Glycogen Storage Disease Type IV.
Journal: The American journal of pathology
Published: April 30, 2025
Progressive liver disease and dysregulated glycogen metabolism in murine GSD IX γ2 models human disease.
Journal: Molecular genetics and metabolism
Published: October 23, 2024
Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease.
Journal: The journal of gene medicine
Published: October 24, 2022
Characterization of liver GSD IX γ2 pathophysiology in a novel Phkg2-/- mouse model.
Journal: Molecular genetics and metabolism
Published: December 04, 2020
Dermatological findings in COVID-19 patients: Mexican experience.
Journal: International journal of dermatology
Published: April 23, 2020
A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme.
Journal: Molecular therapy. Methods & clinical development
Published: January 17, 2020
Near-zero ventilator-associated pneumonia rates after implementation of a multimodal preventive strategy in a Mexican hospital.
Journal: American journal of infection control
Published: August 02, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026